Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma
jRCT2080223055Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Dec 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Nivolumab with Sorafenib (2 arms). Started Dec 2015; status: completed.
02
Drugs
sorafenibnivolumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080223055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223055.